Literature DB >> 186220

1-Alpha-hydroxycholecalciferol in the treatment of hypocalcaemic psychosis.

J M Gertner, A B Hodsman, J N Neuberger.   

Abstract

Two patients with profound hypocalcaemia due to uraemia and hypoparathyroidism respectively presented with alterations of mental state as their dominant symptom. 1-Alpha-hydroxycholecalciferol (1-alpha-OHD3) was chosen as the principal therapy because of its potency and rapid action. In both patients the plasma calcium was restored towards normal and the symptoms relieved within a very short period. The cases illustrate the role of 1-alpha-OHD3 in severe hypocalcaemia due to two different causes and provide experience on which to base treatment regimes for future patients similarly afflicted.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 186220     DOI: 10.1111/j.1365-2265.1976.tb01983.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  The treatment of hypoparathyroidism with 1alpha-hydroxycholecalciferol.

Authors:  D P Brenton; C E Dent; J M Gertner
Journal:  Calcif Tissue Res       Date:  1977-05

2.  Plasma levels of folates, riboflavin, vitamin B6, and ascorbate in severely disturbed children.

Authors:  D V Siva Sankar
Journal:  J Autism Dev Disord       Date:  1979-03

Review 3.  Light, vitamin D and psychiatry. Role of 1,25 dihydroxyvitamin D3 (soltriol) in etiology and therapy of seasonal affective disorder and other mental processes.

Authors:  W E Stumpf; T H Privette
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Hypercalcaemia in alphacalcidol therapy.

Authors:  C R Paterson
Journal:  Postgrad Med J       Date:  1981-07       Impact factor: 2.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.